Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
570
Trial Sponsor
Clinical Trial Start Date
October 29, 2009
0Primary Completion Date
November 9, 2014
0Study Completion Date
November 16, 2017
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Procedure0
Biological0
Intervention Name
CERE-120: Adeno-Associated Virus Delivery of Neurturin0
Sham Surgery0
Interventional Trial Phase
Phase 10
Phase 20
Participating Facility
Official Name
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease0
Last Updated
April 16, 2020
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Care Provider0
Investigator0
Outcomes Assessor0
Participant0
Study summary
The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
